Actively Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Led by Xynomic Pharmaceuticals, Inc. · Updated on 2025-04-13
413
Participants Needed
38
Research Sites
519 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
CONDITIONS
Official Title
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 2018 years or older at study entry
- Histologically confirmed renal cell carcinoma with clear cell component
- Locally advanced unresectable or metastatic disease
- Measurable disease as assessed by the investigator according to RECIST version 1.1
- No prior treatment with VEGF tyrosine kinase inhibitors
- Up to one prior line of cytokine or immune checkpoint inhibitor treatment allowed if progressive disease is confirmed
- ECOG performance status of 0 or 1
- Adequate baseline organ and hematologic function
- At least 2 weeks since last systemic treatment or radiation before randomization
You will not qualify if you...
- Persistent clinically significant toxicities (Grade 2 2) from previous anticancer therapy (excluding alopecia and certain manageable lab abnormalities)
- Untreated central nervous system metastases
- Additional malignancy requiring treatment within the past 3 years, except non-melanoma skin cancer, carcinoma in situ, or non-muscle invasive urothelial carcinoma
- Poorly controlled hypertension (systolic 2 160 or diastolic 2 100 mmHg)
- New pulmonary embolism or deep venous thrombosis within 3 months before randomization
- QTcF interval greater than 480 msec
- New York Heart Association Class III or IV congestive heart failure
- Use of prohibited medications within 7 days or 5 half-lives before first study drug dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 38 locations
1
University Of UA Cancer Center(UACC)/DH-SJHMC
Phoenix, Arizona, United States, 85004
Withdrawn
2
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Withdrawn
3
UCSF Helen Diller Family Comphrensive Cancer Center - Hemato
San Francisco, California, United States, 94158
Withdrawn
4
Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky, United States, 40202
Completed
5
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
Completed
6
GU Research Network/Urology Cancer Center
Omaha, Nebraska, United States, 68130
Withdrawn
7
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Completed
8
Northwell Health/Monter Cancer Center
Lake Success, New York, United States, 11042
Withdrawn
9
Mainstreet Physicans Care
Rochester, New York, United States, 14642
Completed
10
Precision Cancer Research/Dayton Physicians Network - Treatment
Kettering, Ohio, United States, 45409
Withdrawn
11
Oregon Health and Science University
Portland, Oregon, United States, 97239
Completed
12
St. Luke's Hospital
Easton, Pennsylvania, United States, 18045
Completed
13
HOPE Cancer Center of East Texas
Tyler, Texas, United States, 75701
Completed
14
Medical Oncology Associates, PS (dba Summit Cancer Centers)
Spokane, Washington, United States, 99208
Withdrawn
15
Beijing Cancer Hospital
Beijing, China, 100142
Actively Recruiting
16
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China, 200032
Not Yet Recruiting
17
Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica
Candiolo, Italy, 10060
Withdrawn
18
A.O. Cannizzaro_UOS Oncologia Medica
Catania, Italy, 95126
Withdrawn
19
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica
Meldola (FC), Italy, 47014
Withdrawn
20
Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale
Milan, Italy, 20141
Withdrawn
21
Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica
Naples, Italy, 80131
Withdrawn
22
Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica
Novara, Italy, 28100
Withdrawn
23
Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica
Pavia, Italy, 27100
Withdrawn
24
Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria
Pisa, Italy, 56126
Withdrawn
25
Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica
Roma, Italy, '00168
Withdrawn
26
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny
Brzozów, Poland, 36-200
Withdrawn
27
Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii
Gdynia, Poland, 81-519
Withdrawn
28
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym
Krakow, Poland, 31-826
Completed
29
Clinical Research Center Sp. z o.o., Medic-R Sp. K.
Poznan, Poland, 60-848
Withdrawn
30
National Cancer Center - Center For Prostate Cancer
Goyang-si, South Korea, 10408
Completed
31
CHA Bundang Medical Center, CHA University
Seongnam-si, South Korea, 13496
Completed
32
Severance Hospital, Yonsei University Health System - Medical Oncology
Seoul, South Korea, 03722
Completed
33
Asan Medical Center - University of Ulsan College of Medicin
Seoul, South Korea, 05505
Completed
34
Samsung Medical Center - Hematology-Oncology
Seoul, South Korea, 06351
Withdrawn
35
H.G.U. de Elche
Elche, Spain, 03203
Withdrawn
36
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain, 28040
Withdrawn
37
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Completed
38
H.U. Virgen de la Victoria
Málaga, Spain, 29010
Withdrawn
Research Team
S
Sophia Paspal, Ph.D.
CONTACT
R
Rahul Aggarwal, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here